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The challenges of glycan recognition with natural
and artificial receptors
Stefano Tommasone, a Francia Allabush, a Yazmin K. Tagger,a Joshua Norman,a
Monika Ko¨pf,a James H. R. Tucker b and Paula M. Mendes *a
Glycans – simple or complex carbohydrates – play key roles as recognition determinants and modulators
of numerous physiological and pathological processes. Thus, many biotechnological, diagnostic and
therapeutic opportunities abound for molecular recognition entities that can bind glycans with high
selectivity and affinity. This review begins with an overview of the current biologically and synthetically
derived glycan-binding scaffolds that include antibodies, lectins, aptamers and boronic acid-based
entities. It is followed by a more detailed discussion on various aspects of their generation, structure and
recognition properties. It serves as the basis for highlighting recent key developments and technical
challenges that must be overcome in order to fully deal with the specific recognition of a highly diverse
and complex range of glycan structures.
1. Introduction
Glycans occur as free polysaccharides or as mono, oligo or
polysaccharides conjugated to a wide variety of biological mole-
cules, which include glycoproteins, glycolipids and peptidogly-
cans (Fig. 1). In contrast to RNA, DNA and protein synthesis,
glycan biosynthesis is not a template-driven process. Instead,
glycans are assembled by the expression and activity levels of a
series of enzymes present in cells via glycosylation.1 Despite
being generated from a limited number of monosaccharides,
glycans are characterised by a remarkable structural diversity
due to the nature and sequence of the constituent units, the
possible branching of the carbohydrate chains and the configu-
ration and position of glycosidic linkages. Monosaccharides
have multiple hydroxyl moieties that can serve as linking
groups, and the glycosidic bond at the anomeric carbon can
have either a or b stereochemistry, leading to a wide range of
potential linkages between twomonosaccharide units. Furthermore,
glycans can be further diversified by a range of modifications,
including sulfation, phosphorylation, and acetylation. It is this
diversity that makes glycans perform a vast array of biological
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functions and play important roles in various physiological and
pathophysiological events, including cell growth, cell signaling, cell–
cell interactions, differentiation and tumour growth.2,3
Glycans carry information in biological systems that make
them an important source of biomarkers for a wide range of
diseases, including neurodegenerative diseases, hereditary dis-
orders, immune deficiencies, cardiovascular diseases and many
types of cancers.4–6 During the development and progression of
these diseases, glycan expression is altered due to misregulation
of enzymes such as glycosyltransferases and glycosidases, leading
to changes in glycan structures that can potentially be used to
accurately identify the disease at an early stage. In addition to their
clinical value in disease diagnosis and management, glycans are
an emerging class of therapeutics,7 ideal markers for identifying
and isolating specific cell types, including stem cell lineages for
therapeutic transplantation,8 and among other facets, they are key
targets in drug discovery.9 Regarding the latter, glycans are present
on the surface of a variety of pathogens and malignant cells,
making them ideal targets for vaccines.
The recognition of glycans by other molecules with high
aﬃnity and exquisite specificity is at the heart of current and
further developments in glycan-related basic research and clinically
relevant diagnostics and therapeutic applications. However, there
are unique challenges associated with such recognition processes
since the glycan-binding entities need to be able to discriminate
between a large repertoire of carbohydrate structures, including
closely related isomers. Subtle diﬀerences, such as the stereochem-
istry of a single hydroxyl group, make selective recognition hard to
achieve. Moreover, strong solvation in water poses another major
challenge since receptors must be able to compete with an extensive
network of hydrogen bonds surrounding the glycans. Unlike nucleic
acids or proteins, it is diﬃcult to recognise glycans using
complementary sequences or specific antibodies. Glycans are
poorly immunogenic, posing major hurdles in the development
of highly selective anti-carbohydrate antibodies.10 While eﬀorts
are underway to tackle the low aﬃnities and promiscuous
specificity of anti-glycan antibodies, other major strategies involving
either lectins,11 aptamers12 and boronic acid derivatives13,14 are
concurrently and actively being pursued (Fig. 2).
This critical review focuses on the recent progress on all the
diﬀerent strategies to achieve superior glycan recognition,
without considering the substantial eﬀorts concentrated on
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the binding of monosaccharides that are extensively reported
elsewhere.15–20 Particular emphasis will be given to the binding
characteristics (i.e. affinity and selectivity) of the glycan-binding
entities and their potential for further structural glycan differ-
entiation. The purpose of this review is not to provide a
comprehensive survey of the literature on antibodies, lectins
and synthetic receptors such as boronic acid derivatives and
aptamers as entities for the recognition of glycans. Rather
examples are provided to highlight main current capabilities
and limitations of biologically- and chemically-derived glycan-
binding scaffolds. These serve as the framework to bring together
as a whole the field of glycan recognition, identify key challenges
across the field and potential avenues for further progress on
creating glycan-binding scaffolds with high affinity and, more
importantly, with great specificity, for a wide, relevant range of
glycan structures. The advantages and drawbacks associated with
the production and use of glycan-binding scaffolds of biological
or synthetic origin are also examined.
2. Anti-glycan antibodies (AGA)
Antibodies are produced by the immune system in response to
a foreign molecule, namely antigen, entering the body. A given
antibody binds specifically only to a small site on its antigen,
called an epitope, which usually consists of a few amino acids
or monosaccharide units. An ideal antibody should have high
specificity and avidity for its antigen. However, glycans pose a
serious challenge to antibody development. While selectivity
has been observed in some auto-AGAs, other AGAs have been
found to interact with the same antigen, even if with diﬀerent
aﬃnities. Development of highly selective anti-glycan antibodies
has been hindered both by the inherently poor immunogenicity
of carbohydrates, labour intensive antigenic material production
and the similarity between various carbohydrate sequences.21
Fig. 2 Glycan recognition can either be achieved using biologically-
derived antibodies and lectins or chemically-derived aptamers or other
smaller synthetic receptors such as boronic acids. While they all rely on
supramolecular interactions, the methods for their generation diﬀer
greatly. These diﬀerences provide opportunities but also diﬀerent types
of challenges to create glycan-binding scaﬀolds with high aﬃnity and
exquisite specificity.
Fig. 1 Examples of glycans that can be found in nature, ranging from glycosaminoglycan polysaccharides to glycoconjugates such as peptidoglycans,
glycolipids and glycoproteins, which can bear tumour-associated antigens.
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There are also diﬃculties in generating anti-glycan antibodies
because a wide variety of complex glycans are intrinsically expressed
in standard host organisms used to produce antibodies.
A vast collection of AGAs are present in human sera and play
critical functions in many immune processes. AGA expression
depends on exposure to both foreign carbohydrate sequences,
as seen on pathogen surfaces, and to sequences from the ‘‘self’’
of the same species (i.e. blood group antigens A and B). Despite
some AGAs exhibiting aﬃnity for naturally occurring glycans, to
date they cannot be considered true auto-antibodies due to
apparent lack of selectivity for native carbohydrate sequences.22
Prevalent natural AGAs in human sera include those to foreign
glycan epitopes such as N-glycolylneuraminic acid (Neu5GC)
and galactose-a-1,3-galactose (a-Gal), antigens responsible for
the rejection of xenotransplanted organs in humans from
pigs.23–25 Other extensively studied AGAs are the anti-blood
group antibodies against A, B and rare ‘Bombay’ type O antigens,
raised in vivo in the absence of respective erythrocyte surface
antigen. They are highly specific and able to differentiate, for
instance, between the glycan structures of the A- and B-antigens,
wherein an acetamido moiety in A is replaced with a hydroxyl
group in B.26
Auto-AGAs found in serum are now useful biomarkers in the
diagnosis of inflammatory and autoimmune diseases, including
multiple sclerosis and Crohn’s disease.27 Cancer patients are
also able to produce anti-glycan antibodies, which opens up the
possibility of their use for early detection of cancer.28,29 While
promising for diagnosis, they are not eﬀective in activating the
immune system and eliminating malignant cells, limiting pro-
gress in generating new immunotherapies against cancer.30–32
Typically, glycan-binding antibodies exhibit lower aﬃnities
(with equilibrium dissociation constant (KD) values in the micro-
molar range for monovalent interactions) than protein-specific
antibodies (with KD values in the nanomolar range).
33,34 However,
aﬃnities can be enhanced by generating antibodies containing two
ormore glycan binding sites, or through non-covalent assembly into
oligomers with multiple binding sites.35,36 The formation of a
multivalent complex can result in higher aﬃnities and enhanced
selectivities.37,38 Remarkably, human antibody 2G12 was found to
bind strongly to HIV-1 glycoprotein gp120 (KD of 5.6 nM) via
formation of a dimer that establishes multiple complex interactions
with the oligomannose epitope of the glycoprotein.39,40 Furthermore,
phage-display technology has been instrumental in generating AGAs
against a broader range of glycans with superior aﬃnity.41–43 Phage
display is an in vitro technique developed in the mid-80s that allows
the study of protein–ligand interactions between a protein fragment
exposed on the surface of a phage particle and a ligand of
interest.44–46 T-nouvelle (Tn) antigen (GalNAca1-Ser/Thr), highly
expressed in various tumours, is an interesting target for cancer
therapy. However, due to its poor immunogenicity, the development
of an anti-Tn antibody is extremely challenging. A novel library
(6  105 variants) of single-chain antibody fragments (scFv) for
the Tn antigen was constructed using phage display technology.41
The best scFv fragments were attached to an antibody constant
region (Fc) and converted to scFv-Fc fusion proteins, which
showed high specificity against the Tn antigen. Phage display
was also utilised to explore the recognition requirements of
2G12 towards gp120.47 A set of amino acid residues on a 2G12
scaffold was varied in a restricted manner in order to identify
the minimal physicochemical requirements for oligomannose
recognition. Investigation of the generated phage display
libraries provided insights into glycan-antibody interactions.
In addition, the study revealed that there was a high degree of
tolerance within the substitution of five to eight residues. Although
in this case the binding affinity was negatively affected, the
antibodies retained specificity for the target glycan, leaving positive
perspectives for future improvements. Phage-display technology,
coupled with new advances in protein engineering, are opening up
new opportunities to tailor key antibody structural features to
endow AGAs with the ability to form high-affinity interactions with
glycan moieties.
A growing understanding of the immunological mechanisms
by which the immune system refines its antibodies, together
with recent technological advances in carbohydrate chemistry
and bioconjugation are also enabling the production of high-
aﬃnity anti-glycan antibodies.48,49 By using Qb virus-like particles
(VLPs) conjugated via copper-catalyzed azide–alkyne cycloaddition
with short synthetic glycans, anti-glycan IgG antibodies with
nanomolar affinity were produced (Fig. 3).48 The controlled glycan
density displayed on the virus-like particles facilitated not only B
but also T cell recognition, which subsequently provided T cells
with help in promoting affinity maturation in B cells.
Similarly to lectin–carbohydrate interactions, AGA–carbo-
hydrate complexes are held together by hydrogen bonds, CH–p,
van der Waals and electrostatic interactions.33,50 However, unlike
lectins, antibodies are able to accommodate longer glycan
epitopes in their binding sites and can generally interact with
all monosaccharide units. Thus, the enveloping capacity of
antibody binding sites can allow for very specific recognition.51,52
A range of experimental techniques, including synthetic chemistry,
antibody engineering, microarray technology and NMR, alongside
computational approaches have been key to elucidate molecular
structural features that modulate glycan–antibody recognition.53–57
In this regard, antibody engineering and molecular modelling have
been applied to demonstrate that in both pyranoside- and
furanoside-antibody systems, the affinity and specificity mostly rely
on CH–p interactions.54 While hydrophobic stacking interactions
and hydrogen bonds are prevalent in the recognition of neutral
glycans by AGAs, ionic interactions have been shown to play a key
role in the binding of charged glycans.55 Such interactions result in
high glycan-antibody affinities (Kd values in the nanomolar range),
which are generally associated with slow dissociation rates. Anti-
bodies bearing positively charged amino acid residues in their
binding domain can similarly recognise charged carbohydrate
antigens, such as 3-deoxy-D-manno-oct-2-ulosonic acid (or Kdo,
a trisaccharide sequence present in Chlamydiae) with KD values
o1 mM.58 Modulation of the electrostatic interactions can
therefore be used to improve the binding properties of anti-
bodies.59,60 Furthermore, combination of microarray screening
and saturation transfer difference NMR provide key information
regarding the role of the amino acid linker, such as serine
or threonine, in the binding process.56 A related approach
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has also been used to elucidate the effects ofmultipleO-glycosylation
states on antibody recognition.57 These and future insights on
the principles governing glycan-antibody interactions are quite
valuable for guiding antibody engineering and creating highly-
specific AGAs.
Well-defined validated specificities are now possible due to,
recent improvements in glycan microarray-based technology.61,62
Over 1000 AGAs have been reported, although many of them
target the same glycan structure, bringing the current total
number of glycans being specifically recognised by AGAs to
one-quarter of the AGAs available.21 Tumour-associated carbo-
hydrates, such as the Tn (GalNAca1-Ser/Thr), Sialyl-Tn, (Siaa2-
3GalNAca1-Ser/Thr), and the Thomsen–Friedenreich (TF) antigen
(Galb1-3GalNAca1-Ser/Thr), have been particularly targeted for
AGA development.63,64 There is also a good number of AGAs for
ABH blood group antigens, Lewis antigens and glycolipids.65–67
Indeed, these developed antibodies are either currently in clinical
trials or already employed in disease treatment. They have also
been used for diagnostic applications, as is the case for the
antibody that targets Sialyl Lewis A for detecting and monitoring
several cancers.68
Despite considerable eﬀorts, many current AGAs display
low aﬃnities for their target glycans and a lack of specificity,
recognising families of structurally related glycans, rather than
a single distinct structure. Furthermore, available AGAs cover a
narrow set of glycan families and epitopes and many important
O-glycans, N-glycans, glycosaminoglycans and modified glycans
(e.g. sulphated glycans) still lack a corresponding antibody.21
AGAs that can discern a specific amino acid residue (e.g. serine
versus threonine) involved in the glycopeptide bond are also
needed. Therefore, there are still many opportunities for the
development of new AGAs for impacting on basic research, as
well as for new diagnostic and therapeutic applications. Innovations
in and beyond the initial phage display technology and
their combination with other emergent technologies, as well
as advances in glycan synthesis and glycan arrays for high-
throughput AGA analysis, are expected to play a key role in
creating a larger repertoire of AGAs with high binding aﬃnities
and selectivities.
3. Lectins
Lectins are carbohydrate-binding proteins of non-immune origin
that are present in plants, animals and microorganisms. They are
involved in many physiological events and currently play a crucial
role as tools for glycan probing, purification of glycoproteins, cell
labelling, carriers in targeted therapies and detection of cancer
and other diseases.69–71 Lectins display relatively weak affinities
for monosaccharides, with dissociation constants (KD) in the
millimolar range. Affinities are still generally in the micromolar
range for oligosaccharides and glycans, despite the opportunity
for multiple contacts with the surface of the lectin. This is due to
the shallow binding pockets at the lectin surface, which is
exposed to competitive solvent interactions. The absence of
deeper binding pockets can also explain their poor selectivities
for individual sugars. However, in biological settings, some
lectins can assemble into homo-oligomeric structures with
multiple binding sites in order to achieve superior affinity and
selectivity. Thus, an oligomer can interact in an effective manner
with different arms of a branched oligosaccharide or to different
glycan sites of the same glycoprotein. In such oligomeric arrange-
ments, a high degree of multivalency can be reached, contribut-
ing to affinities in the nanomolar range.72–76
Lectins interact with glycans primarily via a network of
hydrogen bonds between the ring oxygen atom and multiple
hydroxyl groups of the carbohydrate residues and oxygen atoms,
amide and hydroxyl groups of the protein, as well as van der
Waals contacts.72,77,78 Nevertheless, CH–p interactions between
the carbohydrate backbone and aromatic amino acids such as
phenylalanine, tyrosine, or tryptophan also make an important
contribution to the overall binding.77,79 The Ralstonia solanacearum
(RSL) lectin can establish CH–p contacts with the C3, C4, C5
and C6 carbons of a-L-Me-fucoside via the indole ring of a
Fig. 3 Synthetic scheme illustrating the functionalization of Qb VLPs with two oligosaccharide antigens (Ag), TS14 and TS3;m represents the number of
antigens per VLP. Reproduced from ref. 48 with permission from the American Society for Clinical Investigation, copyright 2017.
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tryptophan residue, with the dispersion interactions contributing
to the binding with an energy between 7 and 8 kcal mol1.80
Electrostatic interactions become relevant for the recognition of
charged carbohydrate residues, as in the case for negatively
charged sialic acids. In this regard, positively-charged arginine
residues are often involved in sialic acid interaction processes.81
Examples of intermolecular contacts between lectins and glycans
at the binding site can be found in a study reporting the
investigation of the complexation of Siglec-8 lectin and its target,
60-sulfo sialyl Lewis X (60S sLex) (Fig. 4).82 Among several other
interactions between the lectin and the glycan, the carboxyl
group of the sialic acid residue makes a salt bridge with the
guanidinium group of Arg109. Moreover, Lys116 and Ser118
engage in a network of hydrogen bonds with the N-acetyl amide
and the O8 and O9 hydroxyl groups of the glycerol chain. In
addition, the binding is promoted by hydrophobic contacts with
the surrounding aromatic rings of other amino acid residues
such as Tyr11 and Trp117. The binding of the Gal6S is mediated
by the side chains of three residues (Arg56, Tyr58, and Gln59),
together with a salt bridge with the guanidinium group of Arg56
and/or a hydrogen bond with the amino group of Gln59.
The carbohydrate binding activity of C-type lectins, which are
involved in many cell surface recognition events, is mediated by
Ca2+ ions that coordinate carboxylate residues.83,84 Dectin-2, a
C-type lectin specific for high-mannose glycans can for instance,
trigger a defence response against pathogens in a Ca2+-dependent
process.85,86
Currently, several hundred lectins have been identified, with
about 100 lectins commercially available. A major breakthrough
in the use of lectins for glycan recognition came from the
development of the lectin microarray. The technique relies on
the immobilization of a panel of lectins on a solid support that
allows for high-throughput analysis of complex carbohydrates
included in serum glycoproteins, bacteria and whole cells.69,87,88
The advantage of lectin microarrays over other conventional
glycan characterization techniques, namely mass spectrometry,
NMR spectroscopy and liquid chromatography, is the possibility
to rapidly obtain a broad profile or fingerprint of the glycans
present in a crude sample, with minute sample consumption
and reduced cost. General information about the glycosylation
pattern can be determined, such as whether it is N-glycosylated,
O-glycosylated, high mannose, core fucosylated, and fully or
partially sialylated, with potential applications in the develop-
ment of disease-related biomarkers.11,87,89–91
Despite the benefits associated with lectin microarrays, the
inherent low aﬃnity and specificity of lectins hinder their
detection performances. In order to improve their binding
properties, researchers have started to focus their eﬀorts on
lectin engineering.92–97 Several types of lectins can be used as
scaffolds, such as L-type, F-type, Galectins and R-type, with
different engineering procedures available (e.g. site-directed
mutagenesis, random mutagenesis and DNA shuffle to name a
few).97 Recently, the engineering of a bacterial F-type lectin
domain (FLD) from Streptosporangium roseum, namely SrFLD,
showed significantly improved binding towards multivalent
fucosylated glycoconjugates.98 The engineered lectin, SrDupFLD,
contained a partial duplication of the original FLD sequence,
affording two possible L-fucose binding pockets. Binding studies
showed that the engineered lectin had a stronger binding for
multivalent fucosylated glycoconjugates, with a dissociation con-
stant 12-fold lower than the wild-type lectin SrFLD. Analogously,
lectins in which the L-fucose binding residues of the N-terminal
partial FLD region and the complete FLD region were mutated,
respectively SrDupTMFLD and SrDupFLDTM, and were expressed
and purified. Increased binding avidity was observed for
SrDupTMFLD. Against what was its original hypothesis, the
study revealed that the increased affinity of the engineered
lectins may not be mediated by additional L-fuctose binding
sites in the Dup partial FLD region, instead it could be ascribed
to an increased tendency of the lectins for oligomerization.
An interesting example of how artificial lectins can be created
has been reported by Ribeiro et al.99 They engineered the first
chimeric, bispecific lectin, with two rationally oriented and distinct
recognition surfaces, which are able to bind both fucosylated and
sialylated glycoconjugates (Fig. 5). The chimeric lectin, named FS-
Janus lectin, was obtained by fusing sequences from the lectin of
Ralstonia solanacearum (RSL), which displays strong aﬃnity for
fucose, and a sequence from the NanI sialidase of Clostridium
perfringens ATCC13124 (CBM40_NanI), with strong aﬃnity for
sialylated oligosaccharides. The binding ability towards fucose,
30-sialyllactose (30-SL) and 60-sialyllactose (60-SL) functionalised
surfaces was evaluated using surface plasmon resonance. The
Janus lectin showed nanomolar avidity for fucosylated and
sialylated surfaces, with the latter being an important achievement
since classic lectins usually display low aﬃnity for sialylated
epitopes.
There are many challenges associated with lectin engineering,
including the selection of template lectin, construction of a
mutagenesis library and high-throughput screening methods.
Fig. 4 Schematic illustration of the Siglec-8–60S sLex interaction net-
work. Black dashed lines indicate hydrogen bonds in the depicted struc-
ture; gray dashed lines indicate hydrogen bonds abundantly observed in
other structures of the ensemble. Hydrophobic contacts are shown in
green. Reproduced from ref. 82 with permission from the National
Academy of Sciences, copyright 2016.
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However, as these challenges are overcome, lectins with superior
binding properties will broaden the range of applications.
4. Artificial receptors
For several years, eﬀorts have focused on the design of artificial
receptors that can mimic, or even outperform, the role of
antibodies and lectins as carbohydrate binding entities. While
many studies have targeted monosaccharides, the list of receptors
for more complex systems is considerably shorter. One example is
a set of ditopic diaminopyrrolic structures designed for the
selective recognition of Mana(1–2)Man dimannosides.100 Analo-
gous aminopyrrolic derivatives were able to bind the highly
mannosylated HIV virial envelope glycoproteins gp120 and gp41,
as evidenced by SPR studies, as well as showing antiviral activity
against HIV infection of T-lymphocyte CEM cells.101 Although the
aforementioned derivatives showed good binding properties in
polar organic media, solubility in water was very poor, limiting
their application in aqueous systems. Receptors with impressive
binding abilities in water were obtained by developing polycyclic
cages where parallel aromatic surfaces were connected via
water-solubilising spacers. The contribution of hydrophobic
interactions from the aromatic units, together with hydrogen
bonding established with the spacers, not only allowed the
selective recognition of disaccharides such as cellobiose,102,103
but also more complex targets like maltodextrin104 and poly-
saccharides.105 Other interesting examples of artificial receptors
for disaccharides are cyclic peptides obtained from a dynamic
combinatorial approach, which showed selectivity for trehalose.106
Moreover, polyaromatic nanocapsules were reported to exclusively
bind sucrose in water.107 Interestingly, selectivity arises from the
shape complementarity of the capsules, as well as the establishment
of CH–p interactions with the polyaromatic framework.
The above examples provide interesting insights on some of
the key features that give rise to the selective recognition of
carbohydrates. However, so far, they may lack a direct application to
targets of biological relevance. The rest of this review will focus on
the examination of boronic acid derivatives and aptamers for the
recognition of glycans, since they have been able to provide a more
versatile approach for the development of synthetic receptors for
applications in biological settings.
4.1 Boronic acids
Boronic acids are known for their ability to covalently bind 1,2-
and 1,3-diol groups found in carbohydrates.108 The binding
interaction is reversible and pH dependant. Boronic acids can
readily interconvert in aqueous media from sp2 to sp3 hybridisation
in the presence of a Lewis base, with the resulting tetrahedral
species in equilibrium with the neutral trigonal form. The reaction
with diols in alkaline aqueous solutions leads to the formation of
boronate esters. These features make boronic acids interesting
molecules for the realization of synthetic receptors for carbohydrate
recognition, also named ‘‘boronolectins’’.14,19,109–111
The chemical versatility of boronic acids enables their insertion
into various scaﬀolds, with their integration into polymer back-
bones useful for a variety of biomedical applications.112 Vinyl-
phenylboronic acids can be grafted onto suitably modified
nanoparticles,113 while phenylboronic acid–adamantane conjugates
have been reported to form self-assembled monolayers on the
surface of cyclodextrin vesicles in aqueous solution.114 These
vesicles presented multiple boronic acid receptors on their
surface, which were found to bind monosaccharides with binding
constants in the range of 100–3000 M1. Moreover, a glucose
selective sensor was obtained by the formation of a self-assembled
monolayer of bis-boronic acids on gold surfaces.115 The well-
defined intermolecular distance between the boronic acid
moieties, together with a suitable spatial orientation, resulted
in high selectivity for glucose over other saccharides. These,
and other approaches, could enable boronic acids to find real
life-applications, such as the production of probes for the
sensing of sugars in commercial beverages.116,117
Whereas much of the area of sugar binding by boronic acids,
in particular monosaccharide recognition and sensing, has
Fig. 5 A Janus lectin with two rationally oriented and distinct recognition
surfaces, which are able to bind independently to fucosylated and sialylated
glycoconjugates. (A and B) Two views of crystal structure of RSL-trimer
complexed with six fucose ligands (pdb code 2BT9). (C) Crystal structure of
CBM40_NanI complexed with 30-siallylactose (pdb code 5FRE). (D) Design
of the peptide sequence with two blades of RSL connected to CBM40
through a peptide linker. (E) Schematic representation of the expected
FSJanus lectin presenting six fucose binding sites on the upper face and
three sialic acid binding sites on the bottom face. Reproduced from ref. 99
with permission from The Royal Society of Chemistry, copyright 2018.
Chem Soc Rev Review Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
5 
Se
pt
em
be
r 2
01
9.
 D
ow
nl
oa
de
d 
on
 1
0/
8/
20
19
 1
0:
18
:4
2 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Chem. Soc. Rev. This journal is©The Royal Society of Chemistry 2019
already been well documented elsewhere,14,17,19,110,115 glycan
and glycoconjugate recognition using such reports is still in its
infancy. Promising results have been obtained using boronic
acid-functionalized peptidic receptors that act as fluorescent
sensors. In particular, diboronic acid compounds of this type
could be used to recognise cell surface cancer-associated glycans
in situ, such as Sialyl Lewis X (sLex), with high specificity.118,119
The peptide-based linkers connecting two anthracene–phenyl-
boronic acid moieties were employed to improve water solubility
and biocompatibility. These receptors show great potential as
probes in cancer diagnosis (Fig. 6).
Liposomes bearing boronic acids on their outer surface
showed cell-binding ability, providing a tool for drug delivery
upon binding with the glycans on the cell surface.120,121 Further
studies could lead to the development of probes with applications in
targeted drug delivery, cell labelling and selective imaging.
An eﬀective way to create synthetic carbohydrate receptors is
through Molecularly Imprinted Polymers (MIP) using boronic
acids as functional monomers.13,122–127,167 This approach is
based on the formation of a polymer network around a template
molecule (i.e. a glycoprotein), creating artificial binding sites,
which upon removal of the template can be occupied by
their target.126 The use of boronic acids in MIPs can allow the
realization of lectin-like surfaces for the specific recognition of
glycoproteins, where the controlled orientation of the receptors
around the glycoprotein enables the creation of epitopes
for specific fragments.127–129 The approach is versatile and
efficient and provides surfaces with strong affinities and high
specificities. For instance, a sensor platform with a 30-fold
selectivity for Prostate Specific Antigen (PSA) over other glyco-
proteins was realised.13 A pre-formed complex of PSA-acrylamido
boronic acids was grafted onto a functionalized gold surface,
providing the immobilization of the synthetic receptors in
spatial arrangements specific for the target glycoprotein. In
addition, functionalization of the surface around the template
glycoprotein with oligoethylene glycol moieties enabled to create
PSA-shaped cavities (Fig. 7). Surface plasmon resonance (SPR)
binding studies showed that the nanocavities were specific for
PSA, providing high affinity (Kd = 1.8 mM) and detection at
nanomolar concentrations.
Recently, a strategy using boronic acid-tosyl functionalized
glass slides was introduced for the generation of glycoprotein
microarray platforms for glycan profiling.130 The method
allows for the immobilization of glycoproteins from complex
biological samples, and provides a high throughput alternative
for the direct screening of glycan sequences, bypassing the use
of multiple techniques and tedious sample preparation. Imple-
mentation of this approach could find real-life application in
cancer diagnosis.
According to the examples reported above, the use of boronic
acids seems very promising for the construction of synthetic
receptors for glycan recognition. There is great potential for the
development of sensor devices with applications in several areas,
such as biomedical diagnostics and pharmaceutical industry.
However, there are some limitations. In fact, boronic acids show
good binding ability towards sugars in the furanose form,14
Fig. 6 Molecular structures of BPFSs: peptide sequences are reported
with the single-letter amino acid code. Reproduced from ref. 119 with
permission from Springer Nature, copyright 2013.
Fig. 7 Strategy for the fabrication of glycoprotein-imprinted surfaces using acrylamido-boronic acids (AM-BAs); (step 1) self-assembled monolayer
(SAM) formation on a gold surface with DFC molecule; (step 2) incubation of the AM-BA receptors with the template target glycoprotein; (step 3) grafting
of the preformed boronic acid–glycoprotein complex on the SAM via acrylamide co-polymerization; (step 4) azide-terminated oligoethylene glycol (Az-
OEG) functionalization to provide glycoprotein-shaped cavities; (step 5) removal of the template protein, affording a nanocavity specific for the target
glycoprotein. Reproduced from ref. 13 with permission from The Royal Society of Chemistry, copyright 2015.
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while most of the carbohydrates in biologically relevant molecules
are in the pyranose form. Besides, the best binding constants
are observed at alkaline pH values, which might not be com-
patible with some biological systems. Further studies should be
focused on enhancing binding under physiological conditions,
as well as improving glycan recognition with higher selectivities
and specificities.
4.2 Benzoboroxoles
Benzoboroxoles are derivatives of phenylboronic acids with an
intramolecular five membered-ring containing the boron atom.
Although they were first reported in 1957,131 these compounds
only started gaining greater attention in the late 2000s as their
interesting biological activity and hence medicinal relevance,
started to become apparent. Several compounds display anti-
fungal action with some under clinical trials for psoriasis and
human African trypanosomiasis.132,133 In addition, benzoboroxoles
also show inhibitory activity against several enzymes such as carbo-
nic anhydrases and they are potential anti-tuberculosis agents.134,135
However, this class of compound has recently drawn particular
interest from their potential application as carbohydrate receptors,
as they can bind sugars under physiological conditions.136
Compared to their boronic acid counterparts, benzoboroxoles are
able to bind sugars in the pyranose form, at pH values that aremore
suitable for biological systems. This makes them attractive as
potential candidates for the development of synthetic lectins for
the recognition of glycans on cell surfaces and glycoproteins.
Low molecular weight peptidyl bis(benzoboroxole) receptors
were reported to be able to target the cancer-related Thomsen–
Friedenreich (TF) antigen.137 The receptors consisted of two
benzoboroxoles for binding the two diol units of the TF antigen,
and also a peptide backbone, with a tuneable length and rigidity,
to provide additional hydrogen bonding and hydrophobic/CH–p
interactions (Fig. 8). Even small changes in the stereochemical
configuration of the peptide spacer considerably affected the
binding, highlighting the extent to which molecular recognition
is sensitive to subtle variations. Screening for the binding of TF
antigen using a competitive ELISA assay showed that the most
potent receptor exhibited a IC50 value (the concentration of
inhibitor required to produce 50% inhibition of an enzymatic
reaction at a specific substrate concentration) of 20 mM. Although
only moderate affinities and selectivities were observed (Kd in the
low millimolar range) the results are promising and encouraging
for future studies.
The attractive binding properties of benzoboroxoles have
recently led to the development of a carbohydrate-binding ligand
for the specific enrichment of glycoproteins.138 A benzoboroxole-
modified ligand with a structure that mimics Trp and Phe (two
amino acids frequently present in lectins) was immobilised on a
Sepharoset column. This approach allowed the purification of
glycoproteins from complex mixtures at neutral pH. When
glucose oxidase (GOx) was spiked into an E. coli supernatant,
purification with the benzoboroxole-modified column aﬀorded
GOx with 98% purity, with the protein retaining its enzymatic
activity. Thermo-responsive polymers functionalised with benzo-
boroxole units have also been reported as promising sensing
platforms for the detection of diols and polyols (i.e. catechols,
saccharides and glycopolymers) at physiologically relevant pH
values.139 Moreover, benzoboroxole-containing nanoparticles
have turned out to be promising options for immunological
applications such as internalisation of dendritic cells and con-
trolled antigen release.140 These nanoparticles, stable under
physiological conditions, were obtained by mixing glycopolymers
and a benzoboroxole-containing polymer. Their formation was
promoted by the establishment of dynamic covalent bonds
between the two complementary polymer chains. The study
reported that the nanoparticles can be internalised by dendritic
cells which then dissociate when exposed to the acidic environ-
ment of the organelles. This feature allowed the controlled
release of a preloaded antigen upon internalization, opening
up new opportunities for applications in cancer immunother-
apy. Modified nanoparticles could also provide a tool for the
qualitative screening of glycoproteins, as well as the generation
of probes for cancer cell recognition.141,142 Although reaching
high aﬃnity and specificity is still a challenge, benzoboroxoles
are certainly a very promising class of compounds for the
development of synthetic receptors for glycans and their derivatives,
which no doubt will lead to continued interest in these compounds.
In order to disclose the full potential of synthetic glycan
receptors, future eﬀorts should focus on the fine control of the
spatial arrangements of the ligands. Moreover, the promotion
of additional secondary interactions, such as hydrogen bonding
and CH–p interactions must be considered to achieve selective
molecular recognition.
4.3 Aptamers
Aptamers are synthetically derived, single stranded oligo-
nucleotides that bind to non-oligonucleotide based targets.
They are typically constructed from less than 100 bases, with
sequences determined from the Systematic Evolution of Ligands
Fig. 8 Design of peptidyl bis(benzoboroxoles) for the recognition of TF
antigen; the library was generated by combining diﬀerent spacers R1, natural
and non-natural amino acids, and carboxylic acids as capping groups R2.
Reproduced from ref. 137 with permission from Wiley-VCH, copyright 2010.
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by EXponential enrichment (SELEX) method, first adopted by
Tuerk and Gold.143 Aptamers interact with a variety of targets,
ranging from small molecules to whole cells, with similar, if not
improved, aﬃnities than antibodies.144 There is limited recent
literature on aptamers targeting glycans, with most sources
identifying saccharide-binding sequences from over a decade
ago.145 The relative lack of new developments in this field may
be due to limited options regarding non-covalent binding
interactions between sugars and oligonucleotides. For example,
the absence of charged groups and aromatic ring structures in
simple sugars limits interactions to hydrophobic sites and hydrogen
bonding.146 There have been attempts to overcome this particular
problem by the use of modified aptamers. Oligonucleotides bearing
boronic acid groups have been employed to promote aﬃnities of
aptamers to glycan regions of glycoproteins.147 Although there are
now a few recent reports on this approach,148–150 there are no other
examples of the use of any other modification designed specifically
to enhance glycan–aptamer interactions.
Current advances in this area have focusedmainly on aptamers
that target sugars with charged moieties, such as the sialic acids.
These sugars are known to be overexpressed in cancer cells and
are thus ideal candidates to probe in cancer diagnostics and
therapeutics.151 Kim and co-workers used the SELEX process to
identify an RNA aptamer for the sialic acid, N-acetylneuraminic
acid (Neu5Ac).152 They reported a high aﬃnity (KD of 1.35 nM)
and high selectivity, with very little interaction observed between
the aptamer and non-Neu5Ac containing oligosaccharides. They
attribute these properties to the directional immobilisation
approach undertaken for the selection of the aptamer (Fig. 9).
Typically, in SELEX rounds utilising solid supports, target
molecules with multiple functional groups are immobilised in
random orientations, leading to oligonucleotide pools recognising
various epitopes of the same target but with reduced specificity
towards a particular epitope. By directing the immobilisation of
Neu5Ac to adopt a more natural conformation by exposing the
carboxylic acid group of the sugar, the authors were able to
identify an aptamer highly selective for both Neu5Ac alone and
Neu5Ac modified glycans. The binding of the aptamer to
Neu5Ac was also shown to prevent enzymatic hydrolysis of
the sugar. In another study, six DNA aptamer sequences which
specifically targeted another member of the sialic acid family,
N-glycolylneuraminic acid (Neu5Gc), were identified. One of the
aptamers produced a high aﬃnity constant (KA) of 6.68 
109 M1.153 The technology was later developed into aptamer-
nanoparticle biosensor strips for visual detection of Neu5Gc.154
Both of the examples above highlight the latest use of aptamers
as novel probes targeting sialic acids, for rapid and eﬀective
sensing of this particular type of glycan.
Specific DNA aptamers have been also generated to recognise
cell-surface based glycoconjugates. One such target is the cancer
antigen, glycosphingolipid Globo H,155 the binding of which
was enhanced by extending the strands of the aptamers, resulting
in dissociation constants in the low micromolar range. The
specificity of the aptamers towards Globo H was also investigated.
However, the probes showed comparable aﬃnities to oligosac-
charides similar in structure to Globo H. Another target is
membrane-bound N-acetylgalactosamine (GalNAc). A fluorescently
tagged aptamer selected for GalNAc was used to image HeLa and
Cos-7 cells with precise localization.156
Other recent developments have reported aptamers which
target peptidoglycans and glycan regions of glycoproteins. For
instance, RNA aptamers have been selected against two classes
of glycosaminoglycans, heparosan and chondroitin.157 The
non-immunogenic nature of these glycosaminoglycans had
previously made their detection in biological samples using
popular antibody based technologies diﬃcult. High aﬃnities
were observed, with KD values in the range of 0.71–1.0 mM. An
RNA aptamer that binds specifically to the glycosylated receptor-
binding domain of a hemagglutinin protein on the surface of
the influenza virus (HA1, subtype H5) has also been isolated.158
The binding of the aptamer to the glycoprotein blocked attach-
ment of the virus to host cells, indicating a potential use of the
aptamer as an antiviral reagent against influenza.
Apart from RNA aptamers, DNA aptamers that selectively
bind glycan domains in glycoproteins have also been developed.
For instance, DNA aptamers have been shown to target only the
glycan moiety of the prostate cancer biomarker, prostate-specific
antigen (PSA).159 Counter SELEX rounds were introduced to
remove sequences showing aﬃnity for non-glycosylated PSA.
The selected sequences were able to discriminate human PSA
Fig. 9 SELEX process used to enhance selectivity of sequences towards a
particular epitope. Target glycan is immobilised to a solid support in either
a random orientation (A) resulting in reduced selectivity, or a directed
orientation (B) resulting in high selectivity.
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from the non-glycosylated protein but exhibited comparable
aﬃnities to a similarly glycosylated protein (lipocalin-2). To
overcome this problem, the authors utilised their glycan targeting
PSA aptamer along with the anti-PSA aptamer (shown to bind
only to protein regions of PSA) in a sandwich assay for quanti-
fication of human PSA (Fig. 10). The assay displayed enhanced
selectivity for human PSA over both non-glycosylated PSA and a
similarly sized glycoprotein (NGAL), with a limit of detection of
0.66 ng mL1. While the assay was able to detect human PSA at
low amounts, it was diﬃcult to ascertain whether it could
discriminate between diﬀerent glycan forms of PSA, some of
which are indicative of more aggressive forms of prostate cancer.
Lower readings were obtained for patients with benign prostate
hyperplasia compared to the antibody based ELISA, with the
authors suggesting that the sensor could detect a fraction of PSA
with distinct glycan structures.
Two peptidoglycan-targeting DNA aptamers have also been
identified that displayed high aﬃnities towards Staphylococcus
aureus cells.160 The dissociation constants of the two aptamers
towards peptidoglycan were 0.415 mM and 1.261 mM. It was
observed that the aptamers had similar binding to both Gram
negative and Gram positive bacterial cells, despite the latter
typically consisting of a higher content of and more exposed
peptidoglycan. The probes were selective towards bacterial cells
over human fibroblasts, making them promising tools in the
diagnosis of bacterial infections. DNA aptamers have also been
produced against advanced glycation end (AGE) products to
target macromolecules associated with age related disorders.161
Although results were promising, it was stated that further
testing of the aptamers needed to be performed for safety and
eﬃcacy, before consideration for clinical use.
Although the challenges faced by aptamers mainly stem
from the lack of interactions that these oligonucleotides can
establish with glycans, the easy adaptation of aptamers to
incorporate sugar-binding moieties such as boronic acids, to
enhance interactions, is one way to overcome this limitation.147
The biggest challenge for sensing glycoconjugates using aptamers
appears to be enhancing specificity towards a particular glycan
target. Nevertheless, progress can be achieved by optimising
the aptamer selection process (e.g. by utilising directional
immobilisation and counter SELEX methods), and/or by employing
multiple probes in a sandwich based sensing approach.
5. Advantages and drawbacks of
natural and synthetic receptors
Approaches towards the targeting of glycans based on anti-
bodies, lectins, boronic acid derivatives and aptamers have
their own advantages and drawbacks. Various factors have to
be considered when choosing the appropriate receptor system,
according to the glycan being targeted and the application for
which it is intended. The extended binding sites of antibodies
provide opportunities for enhanced aﬃnities and specificities
for glycan targets. However, these improved binding properties
are currently underexploited due to major technical challenges
associated with the poor immunogenicity of glycans and the
lack of high-throughput methods to evaluate the glycan binding
properties of newly generated antibodies. Nevertheless, high-
throughput analysis methods are available by means of lectin
microarrays, yielding information about the glycosylation state of
glycoconjugates, with potential applications in the development
of biomarkers. Moreover, despite usually showing low binding
aﬃnities and poor selectivity for glycans that share the same
extremity, lectins can display higher aﬃnities when assembled
into oligomeric structures.
Thanks to their chemical versatility that allows for the
introduction of various functional groups, boronic acid derivatives
can be incorporated into diﬀerent scaﬀolds, namely surfaces,
nanoparticles or vesicles, unlocking new opportunities for the
creation of sensing devices with potential applications in diagnostics.
A major drawback arises from the strong pH dependence of the
binding, which is favoured at alkaline pH. In this regard, benzobor-
oxoles can overcome the issue since they are able to bind sugars
under physiological conditions, therefore being more compatible
with biological targets. Although selectivity can be achieved, binding
constants are usually in the low millimolar/micromolar range. Small
changes in the structure of the receptor can aﬀect the binding
significantly, hence the accurate tuning of the spatial orientation of
the binding units is essential.
Fig. 10 Prostate specific antigen (PSA) biosensor utilising both glycan and protein binding aptamers in a sandwich based sensing approach: (a) biosensor
set up; (b) data showing selectivity of the sensor towards glycosylated PSA (hPSA) over the non-glycosylated version (rPSA) and a similarly sized
glycoprotein (NGAL). Reproduced from ref. 159 with permission from Elsevier, copyright 2019.
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Aptamers, like boronic acid derivatives, possess heightened
stability and amenability to chemical modification compared to
antibodies and lectins, whilst displaying similar or even higher
aﬃnities for glycan targets. Current research appears to be
focused on the detection of specific glycan-containing biomarkers,
including the sialic acid family and various glycoproteins such as
PSA, for disease diagnostics and therapeutics. Future eﬀorts should
be dedicated to tackling the selectivity challenge concerning
aptamer technology, improving the so far limited techniques
that aim at tweaking the aptamer selection process to focus on
particular epitopes and exclude sequences that bind molecules
similar in structure to the target glycan.
All the glycan-binding entities described in this review show
great potential, although there are still important challenges
that must be tackled in order to successfully achieve specific
glycan recognition. Research on antibodies is moving towards
the rational design of glycan derivatives to improve immuno-
genicity, and glycan arrays to speed up antibody screening and
advances in carbohydrate chemistry to create more complex
glycans. However, antibody production still remains a complicated
and costly procedure and, thus, in many settings, lectins, boronic
acid-based entities and aptamers represent highly suitable and
attractive alternatives. Many eﬀorts are currently focussed on lectin
engineering and despite the several diﬃculties associated with the
creation of artificial lectins, recent studies have shown that superior
aﬃnities for glycans can be achieved. Moreover, for both boronic
acid derivatives and aptamers, the identification and introduction of
functionalities able to establish additional interactions with the
substrate of interest will be crucial for the development of more
eﬀective receptors. Due to the vast amount of hydroxyl groups,
hydrogen bonding is probably the most sought-after type of
interaction,15,20,100,162 followed by CH–p interactions between
glycan backbones and aromatic molecules.107,163 Structural
features (i.e. the size of the aromatic substituents or the
presence of electron-rich groups) can have a significant impact
on the stability of the stacking complexes.164 Finally, the establish-
ment of electrostatic contacts in the appropriate positions can
afford enhanced binding affinities, particularly with charged mole-
cules such as glycosaminoglycans.165,166 As technology continues to
advance, progress is expected in all these areas of research.
6. Summary and outlook
Glycans are of great importance in signifying disease states and
in fundamental biological processes. The diversity of possible
monosaccharide combinations, linkages and modifications,
require a variety of strategies to achieve the selective recognition
of biomedically relevant glycans and their derivatives. In this
regard, various approaches, based on antibodies, lectins, aptamers
and boronic acid derivatives, have been pursued. While these
approaches already contribute to cancer biomarker research,
diagnostics and therapeutics, the development of new and better
glycan binding entities would be invaluable, coupled with better
tools to investigate these targets in various biological settings,
including in vitro and in vivo conditions. Furthermore, there is the
need for more powerful high-throughput screening methods
(i.e. fluorescence methods, UV and SPR) and eﬃcient synthetic
methodologies for the synthesis of complex glycans in high
yield. Finally, a common major challenge across natural and
synthetic receptors is enhancing the selectivity of the receptor
towards a specific glycan target. Thus, the development of new
glycan binding entities will continue to be a high priority for the
foreseeable future.
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